Search Results - "Kleczko, Emily K."

Eicosanoids in Cancer: New Roles in Immunoregulation by Johnson, Amber M, Kleczko, Emily K, Nemenoff, Raphael A

“…Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily through the action of cytosolic phospholipase A2-α. Three major…”
Get full text

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer by Kleczko, Emily K, Kwak, Jeff W, Schenk, Erin L, Nemenoff, Raphael A

“…Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances…”
Get full text

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities by Kleczko, Emily K, Heasley, Lynn E

“…Receptor tyrosine kinase (RTK) pathways serve as frequent oncogene drivers in solid cancers and small molecule and antibody-based inhibitors have been…”
Get full text

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models by Sisler, Daniel J., Hinz, Trista K., Le, Anh T., Kleczko, Emily K., Nemenoff, Raphael A., Heasley, Lynn E.

“…IntroductionThe KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the…”
Get full text

Upregulation of complement proteins in lung cancer cells mediates tumor progression by Kleczko, Emily K, Poczobutt, Joanna M, Navarro, Andre C, Laskowski, Jennifer, Johnson, Amber M, Korpela, Sean P, Gurule, Natalia J, Heasley, Lynn E, Hopp, Katharina, Weiser-Evans, Mary C M, Gottlin, Elizabeth B, Bushey, Ryan T, Campa, Michael J, Patz, Jr, Edward F, Thurman, Joshua M, Nemenoff, Raphael A

“…, cancer cells respond to signals from the tumor microenvironment resulting in changes in expression of proteins that promote tumor progression and suppress…”
Get full text

Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer by Gadwa, Jacob, Bickett, Thomas E, Darragh, Laurel B, Knitz, Michael William, Bhatia, Shilpa, Piper, Miles, Van Court, Benjamin, Bhuvane, Shiv, Nguyen, Diemmy, Nangia, Varuna, Kleczko, Emily K, Nemenoff, Raphael A, Karam, Sana D

“…BackgroundResistance to therapy is a major problem in treating head and neck squamous cell carcinomas (HNSCC). Complement system inhibition has been shown to…”
Get full text

Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms by Neuwelt, Alexander J, Kimball, Abigail K, Johnson, Amber M, Arnold, Benjamin W, Bullock, Bonnie L, Kaspar, Rachael E, Kleczko, Emily K, Kwak, Jeff W, Wu, Meng-Han, Heasley, Lynn E, Doebele, Robert C, Li, Howard Y, Nemenoff, Raphael A, Clambey, Eric T

“…BackgroundProgrammed death 1/programmed death ligand 1 (PD-1/PD-L1) targeted immunotherapy affords clinical benefit in ~20% of unselected patients with lung…”
Get full text

Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma by Marek, Lindsay A, Hinz, Trista K, von Mässenhausen, Anne, Olszewski, Kyle A, Kleczko, Emily K, Boehm, Diana, Weiser-Evans, Mary C, Nemenoff, Raphael A, Hoffmann, Hans, Warth, Arne, Gozgit, Joseph M, Perner, Sven, Heasley, Lynn E

“…Malignant pleural mesothelioma (MPM) is associated with asbestos exposure and is a cancer that has not been significantly affected by small molecule-based…”
Get full text

The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression by Nguyen, Dustin T, Kleczko, Emily K, Dwivedi, Nidhi, Monaghan, Marie-Louise T, Gitomer, Berenice Y, Chonchol, Michel B, Clambey, Eric T, Nemenoff, Raphael A, Klawitter, Jelena, Hopp, Katharina

“…Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic nephropathy, is characterized by phenotypic variability that exceeds genic…”
Get full text

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity by Kleczko, Emily K., Hinz, Trista K., Nguyen, Teresa T., Gurule, Natalia J., Navarro, Andre, Le, Anh T., Johnson, Amber M., Kwak, Jeff, Polhac, Diana I., Clambey, Eric T., Weiser-Evans, Mary, Merrick, Daniel T., Yang, Michael C., Patil, Tejas, Schenk, Erin L., Heasley, Lynn E., Nemenoff, Raphael A.

“…Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of…”
Get full text

Immune checkpoint activity regulates polycystic kidney disease progression by Kleczko, Emily K, Nguyen, Dustin T, Marsh, Kenneth H, Bauer, Colin D, Li, Amy S, Monaghan, Marie-Louise T, Berger, Michael D, Furgeson, Seth B, Gitomer, Berenice Y, Chonchol, Michel B, Clambey, Eric T, Zimmerman, Kurt A, Nemenoff, Raphael A, Hopp, Katharina

“…Innate and adaptive immune cells modulate the severity of autosomal dominant polycystic kidney disease (ADPKD), a common kidney disease with inadequate…”
Get full text

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases by Kleczko, Emily K, Kim, Jihye, Keysar, Stephen B, Heasley, Lydia R, Eagles, Justin R, Simon, Matthew, Marshall, Marianne E, Singleton, Katherine R, Jimeno, Antonio, Tan, Aik-Choon, Heasley, Lynn E

“…The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of head and neck squamous cell carcinomas (HNSCC), and molecularly targeted…”
Get full text

Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease by Hopp, Katharina, Kleczko, Emily K, Gitomer, Berenice Y, Chonchol, Michel, Klawitter, Jost, Christians, Uwe, Klawitter, Jelena

“…Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and affects 1 in 1,000 individuals. There is accumulating…”
Get more information

CD8 + T cells modulate autosomal dominant polycystic kidney disease progression by Kleczko, Emily K, Marsh, Kenneth H, Tyler, Logan C, Furgeson, Seth B, Bullock, Bonnie L, Altmann, Christopher J, Miyazaki, Makoto, Gitomer, Berenice Y, Harris, Peter C, Weiser-Evans, Mary C M, Chonchol, Michel B, Clambey, Eric T, Nemenoff, Raphael A, Hopp, Katharina

“…Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited nephropathy. To date, therapies alleviating the disease have largely…”
Get more information

Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response by Kleczko, Emily K., Le, Anh T., Hinz, Trista K., Nguyen, Teresa T., Navarro, Andre, Hu, Cheng-Jun, Selman, Ana M., Clambey, Eric T., Merrick, Daniel T., Lu, Sizhao, Weiser-Evans, Mary, Nemenoff, Raphael A., Heasley, Lynn E.

“…Lung cancers bearing oncogenically-mutated EGFR represent a significant fraction of lung adenocarcinomas (LUADs) for which EGFR-targeting tyrosine kinase…”
Get full text

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers by Göke, Friederike, Franzen, Alina, Hinz, Trista K, Marek, Lindsay A, Yoon, Petros, Sharma, Rakesh, Bode, Maike, von Maessenhausen, Anne, Lankat-Buttgereit, Brigitte, Göke, Antonia, Golletz, Carsten, Kirsten, Robert, Boehm, Diana, Vogel, Wenzel, Kleczko, Emily K, Eagles, Justin R, Hirsch, Fred R, Van Bremen, Tobias, Bootz, Friedrich, Schroeck, Andreas, Kim, Jihye, Tan, Aik-Choon, Jimeno, Antonio, Heasley, Lynn E, Perner, Sven

“…FGFR1 copy-number gain (CNG) occurs in head and neck squamous cell cancers (HNSCC) and is used for patient selection in FGFR-specific inhibitor clinical…”
Get full text

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC by Singleton, Katherine R, Hinz, Trista K, Kleczko, Emily K, Marek, Lindsay A, Kwak, Jeff, Harp, Taylor, Kim, Jihye, Tan, Aik Choon, Heasley, Lynn E

“…The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway…”
Get full text

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines by Hinz, Trista K, Kleczko, Emily K, Singleton, Katherine R, Calhoun, Jacob, Marek, Lindsay A, Kim, Jihye, Tan, Aik Choon, Heasley, Lynn E

“…The inhibitory epidermal growth factor receptor (EGFR) antibody, cetuximab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC). Despite…”
Get full text

Renal double negative T cells: unconventional cells in search of a function by Nemenoff, Raphael A, Kleczko, Emily K, Hopp, Katharina

Get full text

Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1 by Sippel, Trisha R, Johnson, Amber M, Li, Howard Y, Hanson, Dwight, Nguyen, Teresa T, Bullock, Bonnie L, Poczobutt, Joanna M, Kwak, Jeff W, Kleczko, Emily K, Weiser-Evans, Mary C, Nemenoff, Raphael A

“…Lung cancer is a heterogeneous disease in which patient-specific treatments are desirable and the development of targeted therapies has been effective…”
Get full text